Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim

Merus (NASDAQ:MRUS) had its target price boosted by analysts at Guggenheim from $93.00 to $111.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s target price suggests a potential upside of 119.89% from the company’s previous close.

MRUS has been the topic of a number of other research reports. Needham & Company LLC dropped their price objective on shares of Merus from $92.00 to $85.00 and set a “buy” rating on the stock in a report on Monday, August 5th. Truist Financial lifted their price target on shares of Merus from $69.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. Lifesci Capital raised shares of Merus to a “strong-buy” rating in a report on Monday, July 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $67.00 price target on shares of Merus in a report on Thursday, July 25th. Finally, Stifel Nicolaus lifted their price target on shares of Merus from $90.00 to $99.00 and gave the company a “buy” rating in a report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merus has an average rating of “Buy” and an average price target of $82.00.

Merus Trading Up 1.0 %

NASDAQ:MRUS traded up $0.52 on Tuesday, reaching $50.48. 273,025 shares of the stock traded hands, compared to its average volume of 723,297. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -18.38 and a beta of 1.12. Merus has a 12 month low of $19.81 and a 12 month high of $61.61. The company’s fifty day simple moving average is $51.18 and its 200 day simple moving average is $50.04.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). The firm had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. Equities analysts anticipate that Merus will post -3.27 EPS for the current fiscal year.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP increased its position in shares of Merus by 7.2% during the 4th quarter. Commodore Capital LP now owns 4,747,373 shares of the biotechnology company’s stock worth $130,553,000 after purchasing an additional 319,301 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in Merus by 3.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,749,401 shares of the biotechnology company’s stock valued at $162,682,000 after acquiring an additional 100,000 shares during the period. Federated Hermes Inc. boosted its holdings in Merus by 6.7% during the 2nd quarter. Federated Hermes Inc. now owns 2,398,800 shares of the biotechnology company’s stock valued at $141,937,000 after acquiring an additional 150,000 shares during the period. RTW Investments LP boosted its holdings in Merus by 18.9% during the 4th quarter. RTW Investments LP now owns 2,373,625 shares of the biotechnology company’s stock valued at $65,275,000 after acquiring an additional 376,861 shares during the period. Finally, Samlyn Capital LLC boosted its holdings in Merus by 11.9% during the 2nd quarter. Samlyn Capital LLC now owns 2,324,195 shares of the biotechnology company’s stock valued at $137,523,000 after acquiring an additional 247,605 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.